By Davit Kirakosyan Piper Sandler initiated coverage on Karuna Therapeutics (NASDAQ:KRTX) with an Overweight rating and a price target of $285.00. The firm believes the...
Investing in mid-cap stocks is essential for investors who prefer a diversified portfolio. These stocks offer a middle ground with regard to the risks and rewards when compared to...
For Immediate ReleaseChicago, IL –December 26, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts...
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.
|Average||290.21 (+49.38% Upside)|
|No. of Analysts||19|